Adjunct omeprazole or resveratrol in non-transfusion dependent thalassemia patients with secondary hemochromatosis: a randomized, double-blind, placebo-controlled trial

Start Date10 Feb 2025

Sponsor / Collaborator

National Research Council of Thailand

[+1]

IRCT20091114002709N61

/ RecruitingPhase 3

The effects of resveratrol supplement on some mediator genes of immunity and inflammation, inflammatory factors, oxidative stress and clinical outcomes in hospitalized acute ischemic stroke patients with enteral feeding in intensive care unit: A randomized triple-blind placebo-controlled trial

Start Date30 Dec 2024

Sponsor / Collaborator

Iran University of Medical Sciences & Health Services

CTRI/2024/12/077531

/ Not yet recruitingNot ApplicableIIT

Nutrigenomic Insights into Thalassemia: Resveratrols Influence on HIF-1a and Clock/BMAL1 Genes Expression, Oxidative Stress and bone mineral density (BMD) of North Indian Thalassemia Patients - NIL

Start Date26 Dec 2024

Sponsor / Collaborator

King George's Medical University

100 Clinical Results associated with Resveratrol

100 Translational Medicine associated with Resveratrol

100 Patents (Medical) associated with Resveratrol

29,629

Literatures (Medical) associated with Resveratrol

31 Dec 2025·Gut Microbes

Gut microbiota-derived 4-hydroxyphenylacetic acid from resveratrol supplementation prevents obesity through SIRT1 signaling activation

Article

Author: Ge, Zhiwen ; Zhao, Shuang ; Ma, Yue ; Zhao, Yuanyuan ; Zhao, Wenting ; Wang, Ruiqi ; Wang, Pan ; Zhao, Xiaoyan ; Wang, Dan

Resveratrol (RSV), a natural polyphenol, has been suggested to influence glucose and lipid metabolism. However, the underlying molecular mechanism of its action remains largely unknown due to its multiple biological targets and low bioavailability. In this study, we demonstrate that RSV supplementation ameliorates high-fat-diet (HFD)-induced gut microbiota dysbiosis, enhancing the abundance of anti-obesity bacterial strains such as Akkermansia, Bacteroides and Blautia. The critical role of gut microbiota in RSV-mediated anti-obesity effects was confirmed through antibiotic-induced microbiome depletion and fecal microbiota transplantation (FMT), which showed that RSV treatment effectively mitigates body weight, histopathological damage, glucose dysregulation and systematic inflammation associated with HFD. Metabolomics analysis revealed that RSV supplementation significantly increases the levels of the gut microbial flavonoid catabolite 4-hydroxyphenylacetic acid (4-HPA). Notably, 4-HPA was sufficient to reverse obesity and glucose intolerance in HFD-fed mice. Mechanistically,4-HPA treatment markedly regulates SIRT1 signaling pathways and induces the expression of beige fat and thermogenesis-specific markers in white adipose tissue (WAT). These beneficial effects of 4-HPA are partially abolished by EX527, a known SIRT1 inhibitor. Collectively, our findings indicate that RSV improve obesity through a gut microbiota-derived 4-HPA-SIRT1 axis, highlighting gut microbiota metabolites as a promising target for obesity prevention.

01 Dec 2025·Current Gastroenterology Reports

Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD

Review

Author: Schneider, Yecheskel ; Christian, Vikram ; Dzwonkowski, Monica ; Rollins, Samantha ; Bahirwani, Janak ; Muratore, Alicia

PURPOSE OF REVIEWInflammatory bowel disease (IBD) can cause significant psychological, physical, and economic burdens on patients and healthcare systems. Studies show over one-fifth of patients will seek nontraditional methods of treatment for managing their symptoms. Understanding the benefits - and potential harms - of these therapies is important to provide holistic and evidence-based care to our IBD patients.RECENT FINDINGSIn this review, we present several studied herbal therapies for the management of both Crohn's disease and ulcerative colitis. These include cannabinoids, Tripterygium wilfordii, Chios mastic gum, Boswellia serrata, Indigo Naturalis, curcumin, resveratrol, and Zingiber officinale. While these herbal remedies have been shown to have anti-inflammatory effects and positive outcomes in IBD patients, larger scale studies are lacking and the use may be limited by bioavailability, lack of standardization of formulations, and adverse reactions. In reviewing the literature, we discuss the current data available including benefits, adverse reactions, and considerations for use surrounding several of the more common herbal remedies used for IBD.

01 Dec 2025·Molecular Biology Reports

Pharmacological approaches to enhance mitochondrial biogenesis: focus on PGC-1Α, AMPK, and SIRT1 in cellular health

Review

Author: Palabiyik, Ahmet Alperen ; Palabiyik, Esra

BACKGROUNDMitochondrial biogenesis is essential for cellular energy balance and metabolic stability. Its dysregulation is linked to various metabolic and neurodegenerative diseases, making it a significant therapeutic target. Pharmacological approaches aimed at enhancing mitochondrial function have gained attention for their potential to restore cellular metabolism.OBJECTIVESThis review examines recent advancements in pharmacological strategies targeting mitochondrial biogenesis, focusing on the roles of PGC-1α, AMPK, and SIRT1, alongside novel therapeutic agents and drug delivery systems.METHODSA systematic review of studies published between 2018 and 2023 was conducted using databases such as PubMed, Web of Science, and Elsevier. Keywords related to mitochondrial biogenesis and pharmacological modulation were used to identify relevant literature.RESULTSVarious pharmacological agents, including resveratrol, curcumin, and metformin, activate mitochondrial biogenesis through different pathways. SIRT1 activators and AMPK agonists have shown promise in improving mitochondrial function. Advances in mitochondria-targeted drug delivery systems enhance therapeutic efficacy, yet challenges remain in clinical translation due to the complexity of mitochondrial regulation.CONCLUSIONPharmacological modulation of mitochondrial biogenesis holds therapeutic potential for metabolic and neurodegenerative diseases. While preclinical studies are promising, further research is needed to optimize drug efficacy, delivery methods, and personalized treatment strategies.

News (Medical) associated with Resveratrol

13 Mar 2025

·www.drugs.com

Red Wine Protects Against Cancer? Maybe Not

THURSDAY, March 13, 2025 -- Red wine has been thought to potentially offer protection against cancer, given its high levels of the anti-inflammatory antioxidant resveratrol. But there’s no clear evidence that red wine lessens cancer risk, a new evidence review has concluded. In fact, neither red nor white wine appears to increase people’s overall cancer risk, researchers recently reported in the journal Nutrients . “We conducted a comprehensive meta-analysis to assess whether red wine is truly a healthier choice than white wine,” co-lead researcher Eunyoung Cho , an associate professor of epidemiology and dermatology at Brown University, said in a news release. “The results revealed no significant difference in cancer risk between red and white wine overall,” Cho said. For the evidence review, researchers pooled data from 42 studies involving nearly 96,000 participants to assess the cancer risks or benefits posed by red or white wine. The resveratrol in red wine might not help against cancer because the body burns through it quickly, researchers said. “Although concentrations of resveratrol are greater in red compared to white wine, studies have demonstrated that resveratrol is metabolized quickly, with nearly 75% excreted via feces and urine,” researchers wrote. While their study found no overall link between wine and cancer, researchers did detect specific risk increases. For example, white wine consumption was linked to a 22% increased risk of skin cancer compared to red wine, researchers said. White wine might be linked to behaviors that increase risk for skin cancer, like indoor tanning or putting on too little sunscreen by the pool, researchers speculated. They also detected a stronger association between white wine intake and increased overall cancer risk among women. However, overall “our findings provided a critical public health message that drinking red wine may not be any better than drinking white wine in terms of cancer risk,” researchers concluded. Alcohol -- specifically, the ethanol in alcoholic beverages -- is broken down by the body into compounds that damage DNA and proteins, contributing to cancer risk, researchers noted. In 2020, heavy drinking was linked to more than 740,000 cancer cases worldwide, accounting for 4% of all cases, researchers said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

06 Feb 2025

·www.globenewswire.com

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Feb. 04, 2025 -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials. “The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have been no undisclosed material developments,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Our recent announcements, including partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions, are important milestones in advancing JOTROL™ for our planned Phase 2a study in Parkinson’s disease. With these partnerships in place, we are making tangible progress in our clinical development and remain confident in the path ahead.” Jupiter is advancing a robust clinical pipeline addressing combined market opportunities exceeding $50 billion. The Company is focused on significant unmet needs in CNS disorders, including Alzheimer’s, Parkinson’s, and rare diseases such as MPS-I, Friedreich’s Ataxia, and MELAS. With multiple Phase 2 trials scheduled to launch within the next 12 months—leveraging successful Phase 1 data demonstrating safety—Jupiter is well-positioned for meaningful clinical advancements. In addition to its clinical pipeline development, Jupiter is poised to generate near-term revenue with the upcoming launch of its direct-to-consumer product line in 2025. This initiative represents a key step in diversifying the Company’s business model, providing immediate cash flow while continuing to advance its pharmaceutical pipeline. Focused on the longevity and aging market, the Company expects to share more details soon about two initial products leveraging the unique bioavailability and therapeutic advantages of JOTROL™, which has demonstrated significantly enhanced bioavailability compared to traditional resveratrol formulations. Rosén also commented on the Company’s financial strategy: “While we remain open to strategic funding opportunities, we are committed to avoiding toxic debt and ensuring that we maintain a sustainable approach to financing our operations. With $1.76 million in NIH funding secured and an additional $16 million in grants under review, alongside the $11 million raised in our December 2024 IPO, we are well-positioned to advance our clinical and commercial initiatives. Furthermore, our strategic collaborations with Harvard University, Georgetown University, MIT’s Picower Institute for Learning & Memory, and the University of Miami Miller School of Medicine enhance our research and clinical capabilities, while our efforts to build licensing and commercialization partnerships in Asia position us for future global expansion.” “Despite market fluctuations, our commitment to executing on our strategy remains unchanged,” said Rosén. “We believe in the potential of JOTROL™ and our broader pipeline to address neuroinflammatory diseases and aging-related health solutions. Our team remains focused on driving progress, creating value for our investors, and ultimately delivering transformative treatments for patients.” Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. Zina Biopharmaceuticals, co-founded by Professor Charbel Moussa, is a specialized consulting company providing end-to-end trial design and execution solutions as well as regulatory, scientific and medical advice for biotech and pharmaceutical companies. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Study

13 Jan 2025

·www.globenewswire.com

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims to unlock new therapeutic potential for neurodegenerative diseases, longevity, and aging, positioning the Company at the forefront of innovation in neuroinflammation treatments. The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter’s flagship product, overcomes resveratrol’s historical challenges of poor bioavailability and gastrointestinal side effects. With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3. “By adding focus on NLRP3 evaluation, in addition to earlier established biomarkers, we expect to maximize JOTROL’s therapeutic potential in addressing unmet medical needs,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “We believe JOTROL’s ability to inhibit NLRP3, based on multiple published resveratrol trials, makes it an ideal candidate for diseases such as Parkinson’s and Alzheimer’s, and it positions Jupiter to pursue additional collaborations, particularly in the rapidly growing obesity treatment market.” Advancing Parkinson’s and Alzheimer’s Research Preclinical studies at the University of Miami have demonstrated JOTROL’s ability to mitigate key biomarkers of Parkinson’s disease, making this a primary target for Jupiter’s future trials. The company also continues to refine its strategy for Alzheimer’s research, leveraging its prior Phase I pharmacokinetics study funded by the National Institute on Aging. The U.S. Senate’s recent passage of the "National Plan to End Parkinson’s Act" highlights the growing urgency for effective treatments, and Jupiter is aligning its clinical focus to capitalize on this momentum. With a $50 billion market for Alzheimer’s treatments and a $500 million opportunity in Parkinson’s, Jupiter is well-positioned to address these high-value areas. Market Expansion and Strategic Partnerships In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, could enhance weight loss outcomes, opening doors to potential collaborations in the obesity market—a multibillion-dollar industry. The Company is also pursuing expansion in the Asia-Pacific region, driven by strong interest from regional partners. Recent agreements to accelerate clinical development and regulatory approval underscore Jupiter’s commitment to global growth. Why JOTROL is Different JOTROL’s patented micellar delivery system allows resveratrol to reach effective concentrations in the bloodstream without causing gastrointestinal side effects—a longstanding barrier for resveratrol-based treatments. This innovative approach has been validated in peer-reviewed studies and forms the basis of Jupiter’s strategy to pursue regulatory approval across multiple indications. About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. About JOTROL Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.\ Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. About NLRP3 The NLRP3 inflammasome is a critical component of the innate immune system that mediates caspase-1 activation and the secretion of proinflammatory cytokines IL-1β/IL-18 in response to microbial infection and cellular damage. However, the aberrant activation of the NLRP3 inflammasome has been linked with several inflammatory disorders, which include cryopyrin-associated periodic syndromes, Alzheimer’s disease, diabetes, and atherosclerosis. The NLRP3 inflammasome is activated by diverse stimuli, and multiple molecular and cellular events, including ionic flux, mitochondrial dysfunction, and the production of reactive oxygen species, and lysosomal damage have been shown to trigger its activation. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019 Jul 6;20(13):3328. doi: 10.3390/ijms20133328. PMID: 31284572; PMCID: PMC6651423. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@redchip.com

Phase 1

100 Deals associated with Resveratrol

External Link

KEGG	Wiki	ATC	Drug Bank
-	Resveratrol	-	DB02709

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 3	United Kingdom	Sirtris Pharmaceuticals, Inc.	30 Mar 2009
Multiple Myeloma	Phase 3	Denmark	Sirtris Pharmaceuticals, Inc.	30 Mar 2009
Dementia	Phase 3	-	Evolva Holding SA	-
Parkinson Disease	Phase 2	United States	Jupiter Neurosciences, Inc.Startup	-
Alzheimer Disease	Phase 1	United States	Jupiter Neurosciences, Inc.Startup	-
Alzheimer Disease	Phase 1	United States	Protheragen, Inc.	-
Mild cognitive disorder	Phase 1	United States	Jupiter Neurosciences, Inc.Startup	-
Mucopolysaccharidosis I	Phase 1	United States	Jupiter Neurosciences, Inc.Startup	-
Infertility	Discovery	Spain	IVI Madrid SL	13 Mar 2018
Ovarian Hyperstimulation Syndrome	Discovery	Spain	IVI Madrid SL	13 Mar 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03743636 (NICE, CTgov)	Phase 3	Peripheral Arterial Disease	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	anuewslfxj(skkchwhhtk) = zfpegbluaz uebnvleqgb (lqsscuirzj, nukpvwfbsq - wfvqbaeblv) View more	-	14 Jan 2025
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	anuewslfxj(skkchwhhtk) = qiqbtguncp uebnvleqgb (lqsscuirzj, qoophrshcw - fgmzhflgud) View more
ESMO_ASIA2024	Not Applicable	Breast Cancer Nucleolin (Ncl)	-	Resveratrol-loaded porous silicon nanocarriers	pspvoiiuvs(pdtvqqozbm) = oeofebcnfo uwrpwavzpy (ihppsmdvcx ) View more	-	07 Dec 2024
				Free Resveratrol	pspvoiiuvs(pdtvqqozbm) = qcytthywbp uwrpwavzpy (ihppsmdvcx ) View more
Biospace Manual	Phase 2	Peripheral Arterial Disease	90	Nicotinamide Riboside	(wrebgqgnfd) = qvfatnpfog ltsvpnwnlt (wckqrntnhy )	Positive	24 Jun 2024
				Nicotinamide Riboside combination with resveratrol	-
ESC2023	Not Applicable	Marfan Syndrome	57	Resveratrol	psrlvzpnjx(eeazhwystq) = fvjiocywfu opbcalquby (qoiphflydh )	-	26 Aug 2023
NCT02123121 (REVIVE, CTgov)	Phase 2	Mitochondrial Diseases	60	Vegetable cellulose (Vegetable Cellulose)	gfwpnemdfk(ewnhkdbcfp) = zcnceygndh roerxbdluy (mcfhhrzjpv, bonlvsupfh - kmkxauclox) View more	-	27 Jul 2023
				All groups+Resveratrol 1000 mg/day (Resveratrol 1000 mg/Day)	gfwpnemdfk(ewnhkdbcfp) = zwxebkasjr roerxbdluy (mcfhhrzjpv, wwvzadhqnv - kutzwcdjmd) View more
EASL_LCS2023	Not Applicable	-	-	Mangiferin	nmpzvszswu(ygcvvehgdq) = remarkable enhancement in CD8+ cytotoxic effect afhfamassa (rsoruxybvs ) View more	-	20 Apr 2023
				Resveratrol
NCT04400890 (CTgov)	Phase 2	COVID-19	105	Vitamin D3+Resveratrol (Resveratrol With Vitamin D3)	axzgwqdtff(cwqfywelgi) = sgwcpchsyh npoipbfeme (aprgopdtci, hmljsoyzdq - ricckfbfwd) View more	-	24 Feb 2023
				Vitamin D3 (Placebo With Vitamin D3)	axzgwqdtff(cwqfywelgi) = zlirlkaccl npoipbfeme (aprgopdtci, kjlbqrmfpc - kfcoecbwey) View more
NCT03253913 (RESULT, CTgov)	Phase 2	Lymphangioleiomyomatosis	25	Sirolimus+Resveratrol	ksvrwxrepm(bntiabvhcm) = dggwdgiymn bafxujossz (fykstufude, lloavmykhl - qwmtyinizu) View more	-	01 Feb 2023
NCT04867252 (Pubmed \| Endocrine)	Phase 2	Polycystic Ovary Syndrome	88	Metformin and Pioglitazone	kdsengwfyp(admlnbrtzs) = okwyqkgsxl ytloepftic (ogglzbtxrx )	Positive	28 Sep 2022
				Resveratrol and Myoinositol	kdsengwfyp(admlnbrtzs) = pcumupqgiv ytloepftic (ogglzbtxrx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis